

In Fig. 5, bottom left, please change "Peripheral lymphocytes" to
--Peripheral blood lymphocytes--.

Enclosed is a Request for Approval of Proposed Drawing Changes. An
indication of the Examiner's approval of the proposed changes is respectfully requested in
the next Patent Office Communication.

IN THE CLAIMS:

Please amend Claims 5, 13, 14, 16-19, 23, 25, 29-34, 37-40, 42-44 and 46 to
read as follows. A marked-up copy of Claims 5, 13, 14, 16-19, 23, 25, 29-34, 37-40, 42-44
and 46 , showing the changes made thereto, is attached.

5. (Amended) A DNA selected from the group consisting of:

(a) DNA coding for the polypeptide described in claims 1 or 2,

(b) DNA having the nucleotide sequence of 402 to 1331 in the nucleotide
sequence represented by SEQ ID NO: 2,

(c) DNA having the nucleotide sequence of 492 to 1331 in the nucleotide
sequence represented by SEQ ID NO: 2, and

(d) DNA hybridizing under stringent conditions with the DNA described in
any of (a) to (c) and coding for a polypeptide having b1,3-galactosyltransferase activity
capable of synthesizing Galb1-3GlcNAc structure.